Journal article · 2000
Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial
Journal of Clinical Oncology, 18(21), 3690–3698 · Published 1 November 2000 · DOI 10.1200/jco.2000.18.21.3690
In brief
“Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial” is a 2000 journal article by Ronald D. Feld and 4 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 118 citations as of 19 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 118
- Most cited in
- 2016 (4)
- Field-weighted impact
- 2.60
- References
- 30
- Authors
- 5
Abstract
PURPOSE: To compare meropenem, a carbapenem antibiotic, with ceftazidime for the empirical treatment of patients with febrile neutropenia. PATIENTS AND METHODS: A prospective, double-blind, randomized clinical trial was conducted at medical centers in North America and the Netherlands. A total of 411 cancer patients (196 treated with meropenem and 215 treated with ceftazidime), who had… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Feld, R. D., dePauw, B. E., Berman, S., Keating, A., & Ho, W. G. (2000). Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. Journal of Clinical Oncology, 18(21), 3690–3698. https://doi.org/10.1200/jco.2000.18.21.3690
MLA 9
Feld, Ronald D., et al. “Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial.” Journal of Clinical Oncology, vol. 18, no. 21, 2000, pp. 3690–3698. https://doi.org/10.1200/jco.2000.18.21.3690.
Chicago
Feld, Ronald D., Ben E. dePauw, Steven Berman, Armand Keating, and Winston G. Ho. 2000. “Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial.” Journal of Clinical Oncology 18 (21): 3690–3698. https://doi.org/10.1200/jco.2000.18.21.3690.
Harvard
Feld, R. D. et al. (2000) ‘Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial’, Journal of Clinical Oncology, 18(21), pp. 3690–3698. doi:10.1200/jco.2000.18.21.3690.
IEEE
R. D. Feld, B. E. dePauw, S. Berman, A. Keating, and W. G. Ho, “Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial,” Journal of Clinical Oncology, vol. 18, no. 21, pp. 3690–3698, 2000, doi: 10.1200/jco.2000.18.21.3690.
BibTeX
@article{feld2000meropenem,
title = {{Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial}},
author = {Feld, Ronald D. and dePauw, Ben E. and Berman, Steven and Keating, Armand and Ho, Winston G.},
journal = {Journal of Clinical Oncology},
year = {2000},
volume = {18},
number = {21},
pages = {3690--3698},
doi = {10.1200/jco.2000.18.21.3690},
url = {https://doi.org/10.1200/jco.2000.18.21.3690}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 4 | |
| 2017 | 1 | |
| 2018 | 2 | |
| 2019 | 3 | |
| 2020 | 3 | |
| 2021 | 2 | |
| 2022 | 1 | |
| 2023 | 1 | |
| 2024 | 2 | |
| 2025 | 2 |
Its field-weighted citation impact is 2.60: it has been cited 2.60 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- meropenem
- ceftazidime
- febrile neutropenia
- cancer patients
- empirical antibiotic therapy
- carbapenems
- bone marrow transplant recipients
- antibiotic prophylaxis
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Feld, R. D., dePauw, B. E., Berman, S., Keating, A., & Ho, W. G. (2000). Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. Journal of Clinical Oncology, 18(21), 3690–3698. https://doi.org/10.1200/jco.2000.18.21.3690
How many times has this paper been cited?
118 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Ronald D. Feld, Ben E. dePauw, Steven Berman, Armand Keating, Winston G. Ho.
What is the DOI of this paper?
10.1200/jco.2000.18.21.3690, permanently at https://doi.org/10.1200/jco.2000.18.21.3690. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.